These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 8127665)

  • 1. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
    Pachuk CJ; Yoon K; Moelling K; Coney LR
    Nucleic Acids Res; 1994 Feb; 22(3):301-7. PubMed ID: 8127665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M; Kuwabara T; Taira K
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P; Wright LA; Milliken S; Biggs JC
    Exp Hematol; 1995 Aug; 23(9):986-9. PubMed ID: 7543419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H; Mills K; Gibson I
    Leukemia; 1996 Jun; 10(6):1054-64. PubMed ID: 8667643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W; Daskalakis M; Finke J; Dölken G
    FEBS Lett; 1994 Jan; 338(2):175-8. PubMed ID: 8307177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH; Shore SK; Reddy EP
    Leuk Lymphoma; 1996 Aug; 22(5-6):365-73. PubMed ID: 8882949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
    Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
    Leopold LH; Shore SK; Newkirk TA; Reddy RM; Reddy EP
    Blood; 1995 Apr; 85(8):2162-70. PubMed ID: 7718886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of tRNA-embedded dimeric minizymes.
    Kuwabara T; Warashina M; Nakayama A; Ohkawa J; Taira K
    Nucleic Acids Symp Ser; 1997; (37):307-8. PubMed ID: 9586122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
    Wright LA; Milliken S; Biggs JC; Kearney P
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):15-23. PubMed ID: 9512092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on the in vitro cleavage abilities of ribozymes specific to different sites of bcr-abl fusion gene and their induction of apoptosis in K562 cells].
    Feng Q; Sun B; Zhao Y
    Zhonghua Yi Xue Za Zhi; 2000 Feb; 80(2):127-30. PubMed ID: 11798747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK; Nabissa PM; Reddy EP
    Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).
    Wu Y; Yu L; McMahon R; Rossi JJ; Forman SJ; Snyder DS
    Hum Gene Ther; 1999 Nov; 10(17):2847-57. PubMed ID: 10584930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
    Lange W; Cantin EM; Finke J; Dölken G
    Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
    Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
    Snyder DS; Wu Y; Wang JL; Rossi JJ; Swiderski P; Kaplan BE; Forman SJ
    Blood; 1993 Jul; 82(2):600-5. PubMed ID: 8329715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.